MetaCap

Dyne Therapeutics (DYN) vs Telix Pharmaceuticals (TLX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Telix Pharmaceuticals (TLX) has outperformed Dyne Therapeutics (DYN) over the past year, losing 6.1% versus a loss of 26.8%. Dyne Therapeutics is the larger company by market cap ($2.90 billion vs $2.84 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DYN-26.82%TLX-6.06%
+48%+6%-37%
Nov 21, 20251 yearNov 20, 2026
DYN-45.40%TLX-43.64%
+37%-22%-81%
Nov 11, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DYN versus TLX key metrics
MetricDYNTLX
Share price$15.50$8.37
Market cap$2.90B$2.84B
1-day change-3.31%-3.90%
YTD return-20.76%+11.75%
1-year return-26.82%-6.06%
5-year return+5.37%—
P/E ratio (TTM)—83.70
EPS (TTM)$-3.62$0.10
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$803.79M
Revenue growth (YoY)—+55.61%
Net income (latest FY)$-446.21M$-7.13M
Gross margin—53.05%
Operating margin—3.70%
Net margin—-0.89%
52-week high$27.31$13.11
52-week low$14.00$6.28
Distance from 52-week high-43.23%-36.16%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+121.48%+134.89%
Average volume2.94M356.74K
Shares outstanding187.39M339.78M
Employees3221,120
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • TLX has outperformed DYN by 20.8 percentage points over the past year.

About Dyne Therapeutics

DYN stock →

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

Health Care · Biotechnology: Pharmaceutical Preparations · 322 employees

About Telix Pharmaceuticals

TLX stock →

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions.

Health Care · Biotechnology: Pharmaceutical Preparations · 1,120 employees

DYN vs TLX FAQ

Which is bigger, Dyne Therapeutics or Telix Pharmaceuticals?

Dyne Therapeutics (DYN) is larger, with a market capitalization of $2.90B compared with $2.84B for Telix Pharmaceuticals (TLX).

Which stock has performed better over the past year, DYN or TLX?

TLX returned -6.06% over the past 12 months, compared with -26.82% for DYN (price return, excluding dividends). Past performance does not predict future results.

Are Dyne Therapeutics and Telix Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons